Webinar Recorded on July 30, 2014
Click here to download PDF of presentation
Every formulary decision maker needs to make the best
possible decisions about specialty drug treatments. For the long list of specialty pipeline
drugs, the sovaldi situation is likely to be repeated: little data but big ticket prices. This makes it very important that you have
adequate training in how to use and evaluate models, indirect treatment
comparisons and observational research.
- Sean Karbowicz of OmedaRx will use discuss ICER
and how the California Technology Assessment Panel used this methodology to
arrive at its HCV recommendations.
- Lynn Nishida, Assistant VP with Solid Benefit
Guidance, will discuss how her clients are moving into second generation decision
making with the training provided by the CER Certificate program.
NEW! Wanting to get
your CER Certificate but you’re unable to meet us in Boston? Come to this webinar to hear about our new
webinar-based option for your final certificate module 5.